Role of PARP Inhibitors in Cancer Biology and Therapy

by Davar, D., Beumer, J.H., Hamieh, L., Tawbi, H.
Published 2012

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

by Beumer, J. H., Garner, R. C., Cohen, M. B., Galbraith, S., Duncan, G. F., Griffin, T., Beijnen, J. H., Schellens, J. H. M.
Published 2007

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

by Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H
Published 2012

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis

by Tawbi, H. A., Beumer, J. H., Tarhini, A. A., Moschos, S., Buch, S. C., Egorin, M. J., Lin, Y., Christner, S., Kirkwood, J. M.
Published 2013

A Phase I Trial of Isolated Hepatic Perfusion (IHP) Using 5-FU and Oxaliplatin in Patients with Unresectable Isolated Liver Metastases from Colorectal Cancer

by Magge, D., Zureikat, A. H., Bartlett, D. L., Holtzman, M. P., Choudry, H. A., Beumer, J. H., Pingpank, J. F., Holleran, J. L., Strychor, S., Cunningham, D. E., Jones, H. L., Zeh, H. J.
Published 2013

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

by Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K
Published 2013